What does American Gene Technologies do?

American Gene Technologies® International Inc. (AGT) is a private, clinical-stage biotechnology company based in Rockville, Maryland. Founded in 2007, AGT focuses on developing patent-protected gene and cell therapies aimed at providing permanent cures for serious diseases such as HIV, Phenylketonuria (PKU), and liver cancer. The company utilizes a proprietary lentiviral vector platform that allows for the efficient development of new drug candidates. AGT's therapeutic pipeline includes AGT103-T, a candidate for HIV that has completed Phase 1 clinical trials, and a synthetic gene for treating PKU, which has received FDA Orphan Drug Designation. Additionally, AGT is exploring an immuno-oncology approach for liver cancer, targeting solid tumors through innovative stimulation of gamma-delta T cells. The company is supported by accredited investors and has raised approximately $78 million in funding to advance its research and development efforts.